Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11471141 | 0.81 | EDNRA (0.52) | EDNRAMAPTTP53LMNAKMT2A | |
| SCHEMBL12319426 | 0.81 | EDNRA (0.52) | EDNRAMAPTTP53LMNAKMT2A | |
| SCHEMBL4358291 | 0.80 | CA1 (0.51) | EDNRAMAPTTP53LMNAKDM4E | |
| SCHEMBL388034 | 0.80 | MAPT (0.55) | EDNRAMAPTTP53LMNAKMT2A | |
| SCHEMBL31607236 | 0.80 | EDNRA (0.51) | EDNRAMAPTTP53LMNAKMT2A | |
| SCHEMBL11469582 | 0.79 | EDNRA (0.56) | EDNRAMAPTTP53LMNAKMT2A | |
| SCHEMBL23569071 | 0.77 | EDNRA (0.49) | EDNRAMAPTTP53LMNAKDM4E | |
| SCHEMBL14402138 | 0.76 | KMT2A (0.49) | EDNRAMAPTTP53LMNAKMT2A | |
| SCHEMBL23569216 | 0.76 | EDNRA (0.48) | EDNRAMAPTTP53LMNAKMT2A | |
| SCHEMBL18879361 | 0.76 | EDNRA (0.54) | EDNRAMAPTTP53LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070203183-A1 | Diaryl piperidines as CB1 modulators | SCHERING CORPORATION | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203183-A1 | Diaryl piperidines as CB1 modulators | CNR1, CNR2, GPR119 | EDNRA 1340/4885MAPT 1218/4885TP53 4817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.